FilingSEC EDGAR8-K
MaxCyte Reports Preliminary Q3 Revenue and Raises 2026 Guidance
· SEC accepted
StageEarnings
Filing content
MaxCyte announced preliminary Q3 core business revenue of approximately $8.1 million and raised its full-year 2026 revenue guidance to approximately $34 million.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…